<DOC>
	<DOCNO>NCT01186250</DOCNO>
	<brief_summary>The purpose study determine benefit use FDA-approved insulin-sensitizing agent , Pioglitazone , human heart transplant recipient . The objective project ( 1 ) determine pioglitazone effectively treat insulin resistance heart transplant recipient , ( 2 ) determine whether pioglitazone therapy heart transplantation impact development progression cardiac allograft vasculopathy ( CAV ) , form chronic rejection heart transplantation .</brief_summary>
	<brief_title>Clinical Trial Pioglitazone Prevention Cardiac Allograft Vasculopathy After Heart Transplantation</brief_title>
	<detailed_description>CAV , rapidly progressive obliterative disease involve graft coronary artery , lead cause morbidity mortality beyond first year heart transplantation . This common complication occur almost half recipient within 3 year heart transplantation , associate high rate graft failure mortality . Clinical care heart transplant recipient current era greatly limited lack effective treatment option prevent retard progression CAV . CAV appear strongly associate state insulin resistance , present half heart transplant recipient characterize metabolic abnormality include glucose intolerance , dyslipidemia , endothelial dysfunction , high level circulate inflammatory marker . Insulin resistance effectively treat pioglitazone , TZD compound directly affect tissue insulin sensitivity . In study , enroll 32 insulin-resistant heart transplant recipient randomize pioglitazone placebo one-year period . We determine efficacy pioglitazone treatment insulin resistance prevention development progression CAV heart transplantation . The data generate study provide important preliminary data future , larger-scale clinical investigation .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Heart transplant recipient , year 14 posttransplant 2 . Age &gt; = 18 year 3 . Fasting TG/HDL ratio &gt; =3.0 Fasting TG &gt; =150 mg/dL 1 . Diabetes mellitus 2 . Severe liver dysfunction ( ALT &gt; =2.5 x upper limit normal ) 3 . Severe renal dysfunction ( GFR &lt; 30 Stage IV CKD ) 4 . Moderatesevere fluid retention 5 . Clinical echocardiographic sign leave ventricular dysfunction 6 . Contraindication coronary angiography and/or IVUS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cardiac allograft vasculopathy</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>heart transplant</keyword>
</DOC>